drugset / Trial / NCT00401401
Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the safety of zalutumumab in combination with chemotherapy and radiotherapy as treatment of patients with head and neck cancer
Timeline
- Start
- 2006-12
- Primary completion
- 2010-10
- Completion
- 2010-10
Outcome
Outcome not reported
Stopped: “MTD was established and patients completed 16 months safety f-up and response assessments. It is considered of limited value to follow patients for 3 years.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zalutumumab | Monoclonal antibody | 4 mg/kg | — |
| Subject | Zalutumumab | Monoclonal antibody | 8 mg/kg | — |
| Subject | Zalutumumab | Monoclonal antibody | 12 mg/kg | — |
| Subject | Zalutumumab | Monoclonal antibody | 16 mg/kg | — |
| Background | Cisplatin | Other / unclassified | — | — |